Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Theravance Biopharma
TBPH
Theravance Biopharma
Chronic And Respiratory Care Will Fuel Future Market Expansion
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
30 May 25
Updated
15 Aug 25
3
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
US$18.00
26.9% undervalued
intrinsic discount
15 Aug
US$13.15
Loading
1Y
56.9%
7D
15.4%
Author's Valuation
US$18.0
26.9% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
US$18.0
26.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-270m
139m
2014
2017
2020
2023
2025
2026
2028
Revenue US$138.6m
Earnings US$32.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
18.39%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$32.19m
Earnings '28
x
36.76x
PE Ratio '28
=
US$1.18b
Market Cap '28
US$1.18b
Market Cap '28
/
54.94m
No. shares '28
=
US$21.54
Share Price '28
US$21.54
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$17.69
Fair Value '25